REDX Stock Overview
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Redx Pharma Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.10 |
| 52 Week High | UK£0.38 |
| 52 Week Low | UK£0.04 |
| Beta | -0.53 |
| 1 Month Change | -46.67% |
| 3 Month Change | -51.22% |
| 1 Year Change | -68.25% |
| 3 Year Change | -84.96% |
| 5 Year Change | 66.67% |
| Change since IPO | -88.30% |
Recent News & Updates
Shareholder Returns
| REDX | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -21.6% | 8.3% | 2.2% |
| 1Y | -68.3% | 4.9% | 0.9% |
Return vs Industry: REDX underperformed the UK Pharmaceuticals industry which returned 0.2% over the past year.
Return vs Market: REDX underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| REDX volatility | |
|---|---|
| REDX Average Weekly Movement | 30.4% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: REDX's share price has been volatile over the past 3 months.
Volatility Over Time: REDX's weekly volatility has increased from 16% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 101 | Lisa Mary Anson | www.redxpharma.com |
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn’s disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.
Redx Pharma Plc Fundamentals Summary
| REDX fundamental statistics | |
|---|---|
| Market cap | UK£38.90m |
| Earnings (TTM) | -UK£33.16m |
| Revenue (TTM) | UK£4.20m |
9.3x
P/S Ratio-1.2x
P/E RatioIs REDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REDX income statement (TTM) | |
|---|---|
| Revenue | UK£4.20m |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£4.20m |
| Other Expenses | UK£37.36m |
| Earnings | -UK£33.16m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.085 |
| Gross Margin | 100.00% |
| Net Profit Margin | -789.05% |
| Debt/Equity Ratio | 468.9% |
How did REDX perform over the long term?
See historical performance and comparison